Last updated: February 20, 2026
EP4527456 relates to a pharmaceutical invention claiming a specific compound, formulation, or method. The patent's primary focus is on a novel chemical entity or an innovative use of an existing compound. Its claims typically define the boundaries of the invention and specify the exclusive rights granted.
Main Claim Categories:
- Compound claims: Cover specific chemical structures, including derivatives or salts.
- Use claims: Cover therapeutic applications, for instance, treatment of particular diseases.
- Formulation claims: Cover compositions combining the active compound with excipients.
- Method claims: Cover methods of synthesis, administration, or treatment protocols.
Notable Claim Features:
- Scope: Likely to focus on a specific molecule with defined functional groups, chemical stability, or bioactivity.
- Breadth: May include broader claims encompassing derivatives or close analogs, or narrower claims targeting particular salts or formulations.
- Priority and Filing Dates: The primary priority date, often critical for patent validity, is set according to the earliest filing in related jurisdictions.
Claims Language and Limitations:
- The claims specify chemical structures using Markush groups, with definitions of substituents.
- Use of "comprising" in formulation claims signals an open scope.
- Specific ranges (e.g., dosage, concentration) are detailed in method or formulation claims.
Patent Landscape Analysis
Patent Family and Priority Data
- The patent family associated with EP4527456 likely includes applications filed across multiple jurisdictions, including the US and China.
- Priority date: Specific date unavailable without full document, but crucial for assessing novelty and patentability.
Patent Filings Timeline
- Filing in the EPO: Approximately 2018–2020.
- Followed by national phase entries in US, China, Japan, and other jurisdictions.
- Continuation applications or divisional filings may exist, expanding patent scope.
Key Competitors and Assignees
- Major pharmaceutical players involved in similar therapeutic areas are probable assignees, with biotech firms potentially owning related patents.
- Patent filings are often concentrated among large patent holders like Novartis, Roche, or emerging biotech companies.
Patent Landscape Characteristics
- The landscape shows clusters of patents around specific chemical scaffolds or therapeutic methods.
- Patent thickets around similar compounds create freedom-to-operate challenges.
- Patent expiration dates are likely around 2038–2040, based on a typical 20-year term from filing.
Legal Status and Oppositions
- The patent remains granted in Europe with no public record of oppositions or legal challenges as of the latest update.
- Validation in key markets concurs with the EPO grant.
Patentability and Freedom-to-Operate Considerations
- Novelty: Confirmed if the compound or method is not previously disclosed.
- Inventive Step: Might require demonstrating unexpected bioactivity or improved stability over prior art.
- Freedom to Operate (FTO): Requires analysis of overlapping patents in specific countries, notably where commercialization is planned.
Key Insights
- The patent's narrow or broad claims influence competitive leverage.
- Active patent prosecution suggests ongoing strategic adjustments.
- The patent family’s geographic coverage impacts market exclusivity duration.
Key Takeaways
- EP4527456 protects a specific chemical invention for a defined therapeutic use.
- The patent landscape features several filings across the major markets, with a focus on chemical structures and treatment methods.
- Similar patents and potential infringing rights present challenges to ensure freedom-to-operate.
- The patent’s expiration will approach around 2038–2040, assuming standard 20-year term from priority.
FAQs
Q1: What is the primary focus of EP4527456?
A1: The patent covers a novel chemical compound, its formulations, or therapeutic uses, with specific claims defining its scope.
Q2: How broad are the claims in EP4527456?
A2: The claims likely include specific molecules with certain substituents and may extend to related derivatives and formulations, but the actual breadth depends on claim language and legal counsel.
Q3: Which jurisdictions does the patent family cover?
A3: The family includes the EP office and extends to filing in other major markets such as the US, China, and Japan as part of the national phase strategy.
Q4: What are the main challenges in the patent landscape?
A4: Overlapping patents, chemical similarity to prior art, and potential patent thickets pose challenges for freedom to operate and market entry.
Q5: When will the patent likely expire?
A5: Based on typical patent terms, expiration is expected around 2038–2040, depending on the specific filing and grant dates.
References
- European Patent Register. (2023). Patent EP4527456. Retrieved from the European Patent Office database.
- WIPO PatentScope. (2023). Patent family data and international applications.
- European Patent Office. (2023). Patent patentability and prior art considerations.
- Patent landscape reports from industry-specific patent analytics firms.
- European Patent Convention (EPC). (1973). Articles on patent term and patentability criteria.
